Completed

A Randomized, Double-blind, Placebo- and Comparator-controlled Study Evaluating the Effect of Multiple Doses of QGE031 Compared to Omalizumab in Asthma Induced by Allergen Bronchial Provocation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

QGE031

+ omalizumab

+ placebo

Drug
Who is being recruted

Bronchial Diseases+6

+ Hypersensitivity, Immediate

+ Immune System Diseases

From 18 to 65 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 1 & 2
Interventional
Study Start: November 2012
See protocol details

Summary

Principal SponsorNovartis Pharmaceuticals
Last updated: April 20, 2016
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2012

Actual date on which the first participant was enrolled.

This study will evaluate the efficacy of QGE031 compared to omalizumab in patients with allergic asthma. Each treatment's effect in changing the concentration of inhaled allergen that is required to elicit a 15% fall in the forced expiratory volume in one second (FEV1) at 12 weeks compared to baseline will be evaluated.

NCT01703312
Principal SponsorNovartis Pharmaceuticals
Last updated: April 20, 2016
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

37 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Bronchial DiseasesHypersensitivity, ImmediateImmune System DiseasesLung DiseasesLung Diseases, ObstructiveRespiratory HypersensitivityRespiratory Tract DiseasesAsthmaHypersensitivity

Criteria

Inclusion Criteria: Adult patients 18 to 65 years Positive skin prick test to one or more common airborne allergens Presence of airway hyperresponsiveness documented by a provocative concentration of methacholine causing a 20% fall in FEV1 (PC20 FEV1) of less than or equal to 16 mg/mL Presence of an early asthmatic response demonstrated by an allergen challenge at screening and including a 15% fall in the FEV1 Patients with a body weight and total IgE in a range specified by local country prescribing information for omalizumab Exclusion Criteria: Pregnant or nursing (lactating) women Women of child-bearing potential unless they are using a highly effective method of birth control (as further defined in the study protocol) Smokers Patients with poorly controlled asthma or patients who have had an asthma exacerbation within the past year Other protocol-defined inclusion/exclusion criteria may apply.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

33.333% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses). Three dose levels of QGE031 will be offered during the study: low, medium, and high. Participants will be randomized to receive one of these dose levels for all dosing visits.

Group II

Active Comparator
During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses) or once every four weeks (total of three doses). The dose that a participant receives will depend upon the participant's body weight and IgE level; dosage will be determined based upon local omalizumab dosing charts.

Group III

Placebo
During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses).

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 7 locations

Novartis Investigative Site

Calgary, CanadaOpen Novartis Investigative Site in Google Maps

Novartis Investigative Site

Edmonton, Canada

Novartis Investigative Site

Hamilton, Canada

Novartis Investigative Site

Ste-Foy, Canada
Completed7 Study Centers
A Randomized, Double-blind, Placebo- and Comparator-controlled Study Evaluating the Effect of Multiple Doses of QGE031 Compared to Omalizumab in Asthma Induced by Allergen Bronchial Provocation | PatLynk